Xiufeng Pang

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 10

Top Topics

Combination Therapy

Tyrosine Kinase

Advanced Non Small Cell Lung Cancer

Top Venues

Journal of medicinal chemistry

Chinese journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Xuanzheng Xiao, Juanjuan Feng, Jing Ma, Xinting Xia, Xiaogu Liu, Jian Zhang, Chunyong Ding, Xiufeng Pang, Ao Zhang
Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3- d ]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRAS G12D Inhibitors. Journal of medicinal chemistry (2023)
Juanjuan Feng, Zhongwei Hu, Xinting Xia, Xiaogu Liu, Zhengke Lian, Hui Wang, Liren Wang, Cun Wang, Xueli Zhang, Xiufeng Pang
Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS G12D inhibitor efficacy in KRAS G12D -mutated colorectal cancer. Oncogene (2023)
Peng He, Juanjuan Feng, Xinting Xia, Yue Sun, Jia He, Tian Guan, Yangrui Peng, Xueli Zhang, Mingyao Liu, Xiufeng Pang, Yihua Chen
Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance. Journal of medicinal chemistry (2023)
Peng He, Juanjuan Feng, Xinting Xia, Yue Sun, Jia He, Tian Guan, Yangrui Peng, Xueli Zhang, Mingyao Liu, Xiufeng Pang, Yihua Chen
Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance. Journal of medicinal chemistry 66 (9) (2023)
Peng He, Juanjuan Feng, Xinting Xia, Yue Sun, Jia He, Tian Guan, Yangrui Peng, Xueli Zhang, Mingyao Liu, Xiufeng Pang, Yihua Chen
Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance. Journal of medicinal chemistry 66 (9) (2023)
Yanan Liu, Longmiao Hu, Zhengzhen Wu, Kun Yuan, Guangliang Hong, Zhengke Lian, Juanjuan Feng, Na Li, Dali Li, Jiemin Wong, Jie-Kai Chen, Mingyao Liu, Jiangping He, Xiufeng Pang
Loss of PHF8 induces a viral mimicry response by activating endogenous retrotransposons. Nature communications 14 (1) (2023)
Yanan Liu, Juanjuan Feng, Kun Yuan, Zhengzhen Wu, Longmiao Hu, Yue Lu, Kun Li, Jiawei Guo, Jing Chen, Chengbin Ma, Xiufeng Pang
The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress. eLife 11 (2022)
Weikai Guo, Yajing Xing, Qiansen Zhang, Jiuqing Xie, Dongxia Huang, Haijun Gu, Peng He, Miaoran Zhou, Shi-Fen Xu, Xiufeng Pang, Mingyao Liu, Zheng-Fang Yi, Yihua Chen
Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of N-Phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth. Journal of medicinal chemistry 63 (2) (2020)
Weiwei Yu, Weiqiang Lu, Guoliang Chen, Feixiong Cheng, Hui Su, Yihua Chen, Mingyao Liu, Xiufeng Pang
Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo. British journal of pharmacology 174 (20) (2017)
Xiufeng Pang, Mingyao Liu
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS. Chinese journal of cancer 35 (1) (2016)